Gossamer Bio Inc (GOSS) Stock: A SWOT Analysis

Company’s 36-month beta value is 1.74.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for GOSS is 188.84M, and currently, short sellers hold a 5.87% ratio of that floaft. The average trading volume of GOSS on April 03, 2024 was 1.11M shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

GOSS) stock’s latest price update

Gossamer Bio Inc (NASDAQ: GOSS) has experienced a decline in its stock price by -9.45 compared to its previous closing price of 1.27. However, the company has seen a fall of -12.21% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-07 that Gossamer Bio, Inc. (GOSS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GOSS’s 50-day simple moving average broke out above its 200-day moving average; this is known as a “golden cross.

GOSS’s Market Performance

Gossamer Bio Inc (GOSS) has seen a -12.21% fall in stock performance for the week, with a -16.67% decline in the past month and a 26.03% surge in the past quarter. The volatility ratio for the week is 9.53%, and the volatility levels for the past 30 days are at 8.57% for GOSS. The simple moving average for the past 20 days is -15.32% for GOSS’s stock, with a 13.10% simple moving average for the past 200 days.

Analysts’ Opinion of GOSS

Many brokerage firms have already submitted their reports for GOSS stocks, with UBS repeating the rating for GOSS by listing it as a “Neutral.” The predicted price for GOSS in the upcoming period, according to UBS is $1.25 based on the research report published on July 27, 2023 of the previous year 2023.

GOSS Trading at 0.59% from the 50-Day Moving Average

After a stumble in the market that brought GOSS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.83% of loss for the given period.

Volatility was left at 8.57%, however, over the last 30 days, the volatility rate increased by 9.53%, as shares sank -20.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +32.18% upper at present.

During the last 5 trading sessions, GOSS fell by -12.21%, which changed the moving average for the period of 200-days by -8.00% in comparison to the 20-day moving average, which settled at $1.3430. In addition, Gossamer Bio Inc saw 26.03% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at GOSS starting from Hasnain Faheem, who sale 23,172 shares at the price of $1.16 back on Mar 27 ’24. After this action, Hasnain Faheem now owns 120,293 shares of Gossamer Bio Inc, valued at $26,773 using the latest closing price.

Giraudo Bryan, the COO/CFO of Gossamer Bio Inc, sale 6,430 shares at $1.16 during a trade that took place back on Mar 27 ’24, which means that Giraudo Bryan is holding 92,737 shares at $7,431 based on the most recent closing price.

Stock Fundamentals for GOSS

The total capital return value is set at -0.67. Equity return is now at value -480.50, with -61.54 for asset returns.

Based on Gossamer Bio Inc (GOSS), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at -0.75. The debt to equity ratio resting at 3.38. The interest coverage ratio of the stock is -12.86.

Currently, EBITDA for the company is -169.37 million with net debt to EBITDA at -1.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.94.

Conclusion

In a nutshell, Gossamer Bio Inc (GOSS) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts